Connect with us

Cadila seeks nod to repurpose Hepatitis C drug for COVID-19 in India

HBS Reporting

Cadila seeks nod to repurpose Hepatitis C drug for COVID-19 in India

Cadila seeks nod to repurpose Hepatitis C drug for COVID-19 in India

BENGALURU (Reuters) – India’s Cadila Healthcare Ltd has sought approval from local regulators to use a Hepatitis C drug as a treatment for COVID-19 following promising interim results from a late-stage trial, the drugmaker said on Monday.

A single dose of the Hepatitis C drug when taken early could help COVID-19 patients recover faster and avoid complications seen in the advanced stages of the disease, Cadila said in a statement to stock exchanges.

About 91% of patients treated with the drug tested negative for COVID-19 in standard RT-PCR tests by day seven, compared to nearly 79% who were given the standard of care, the company said citing Phase-III clinical trial data.

The drug, known as Pegylated Interferon alpha-2b and branded as ‘PegiHep’ by Cadila, was originally approved for liver disease Hepatitis C and launched in India 10 years ago. It is being repurposed to treat COVID-19.

The news comes as daily coronavirus infections are surging to new highs in India, which has the world’s third-highest caseload after the United States and Brazil. India has so far reported close to 12.5 million infections and more than 164,000 deaths.

Continue Reading
You may also like...
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

More in HBS Reporting

To Top
Translate »